Refine
Year of publication
- 2013 (4) (remove)
Document Type
- Doctoral Thesis (4)
Language
- English (4)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Institute
ß1-integrins are essential for angiogenesis but the mechanisms regulating integrin function in endothelial cells (EC) and their contribution to angiogenesis remain elusive. BRAG2 is a guanine nucleotide exchange factor for the small Arf-GTPases Arf5 and Arf6. The role of BRAG2 in EC and angiogenesis and the underlying molecular mechanisms remains unclear. siRNA-mediated BRAG2-silencing reduced EC angiogenic sprouting and migration. BRAG2-siRNA-transfection differentially affected a5ß1- and aVß3-integrin function: specifically, BRAG2-silencing increased focal/fibrillar adhesions and EC adhesion on ß1-integrin-ligands (fibronectin and collagen), while reducing the adhesion on the aVß3-integrin-ligand, vitronectin. Consistent with these results, BRAG2-silencing enhanced surface expression of a5ß1-integrin, while reducing surface expression of aVß3-integrin. Mechanistically, BRAG2 mediated recycling of aVß3-integrins and endocytosis of ß1-integrins and specifically of the active/matrix bound a5ß1-integrin present in fibrillar/focal adhesions (FA), suggesting that BRAG2 contributes to the disassembly of FA via ß1-integrin-endocytosis. Arf5 and Arf6 are promoting downstream of BRAG2 angiogenic sprouting, ß1-integrin-endocytosis and the regulation of FA. In vivo silencing of the BRAG2-orthologues in zebrafish embryos using morpholinos perturbed vascular development. Furthermore, in vivo intravitral injection of plasmids containing BRAG2-shRNA reduced pathological ischemia-induced retinal and choroidal neovascularization. These data reveals that BRAG2 is essential for developmental and pathological angiogenesis by promoting EC sprouting through regulation of adhesion by mediating ß1-integrin internalization and associates for the first time the process of ß1-integrin endocytosis with angiogenesis.
Fungal organisms, including the most common human pathogens Candida spp., are commensal organisms that are widely present as part of the human flora. Fungal infections are, most frequently, local infections that do not compromise the life of patients. However, mycotic diseases can be life-threatening if they become systemic infections. Systemic fungal infections have risen over the last three decades in parallel to the increased immune-compromised population as a consequence of diseases (e.g. HIV/AIDS) or therapeutic interventions that affect the immune system (e.g. chemotherapy for cancer treatment and immunosuppressors used for patients with organ transplants). This has resulted in the demand of new antifungal drugs that can eradicate the new infections caused by these opportunistic fungal pathogens. However, most of the current compounds have poor pharmaceutical properties such as narrow spectrum of activity, susceptibility to be extruded by efflux pumps or lack of specificity, which make them not suitable for human clinical applications. The treatment of fungal and parasitic infections has been traditionally difficult because the infective organisms are eukaryotic cells that share most of the pathways and enzymes with human cells. To avoid side effects and to develop a targeted therapy, the research has traditionally been centered on the very few enzymes and pathways existing in the infectious organism but absent in humans. Until now, antifungal therapeutic options are limited and are almost dominated by azole class of sterol biosynthesis inhibitors affecting the synthesis of ergosterol, a major constituent of the fungal cell membrane. Because human cells do not have a cell wall, the development of effective and safe antifungal agents has also been directed to enzymes required for the synthesis of the cell wall. Alternatively, it is theoretically possible to target enzymes that are present in fungal organisms and in humans, when: 1) sufficient selectivity can be achieved, and 2) inhibition of the fungal enzyme is lethal to the fungus but does not produce major side effects to humans. In this line, it would be ideal to evaluate the development of selective inhibitors of enzymes which are already known to be drug targets, like protein kinases.
Nervous system development requires a sequence of processes such as neuronal migration, the development of dendrites and dendritic spines and the formation of synapses. The extracellular matrix protein Reelin plays an important role in these processes, Reelin regulates for example the migration of neurons from proliferative zones to their target positions in the brain. As a consequence, layered structures are formed in the neocortex, the hippocampus and cerebellum (Lambert de Rouvroit et al., 1999). Reelin exerts its functions by binding to two transmembrane receptors, apolipoprotein E receptor 2 (ApoER2) and very-low-density lipoprotein receptor (VLDLR). This binding causes phosphorylation of the intracellular adapter protein Disabled-1 (Dab1) (D’Arcangelo et al., 1999) via activation of Src-family kinases (SFKs) (Bock and Herz, 2003), leading to cytoskeletal reorganization which enables cell migration and morphological changes (Lambert de Rouvroit and Goffinet, 2001). Since ApoER2 and VLDLR do not possess intrinsic kinase activity to activate SFKs, the existence of a co-receptor was suggested. EphrinBs are transmembrane ligands for Eph receptors and have signaling capabilities required for axon guidance (Cowan et al., 2004), dendritic spine maturation (Segura et al., 2007) and synaptic plasticity (Essmann et al., 2008; Grunwald et al., 2004). As stimulation of cultured cortical neurons with soluble EphB receptors causes recruitment of SFKs to ephrinB-containing membrane patches and SFK activation (Palmer et al., 2002), we investigated whether ephrinB ligands would be the missing co-receptors in the Reelin signaling pathway functioning during neuronal migration, dendritic spine maturation and synaptic plasticity. We found that the extracellular part of ephrinBs directly binds to Reelin and that ephrinBs interact with Dab1, phospho-Dab1, ApoER2 and VLDLR. EphrinB3 is localized in the same neurons as ApoER2 and Dab1 in the cortex and hippocampus, and in the cerebellum ephrinB2 is detected in neurons that express Dab1. To investigate the requirement of ephrinBs for neuronal migration, triple knockout mice lacking all ephrinB ligands were analyzed. The cortical layering of ephrinB1, B2, B3 knockout brains is inverted, showing the outside-in pattern typical for the reeler cortex. The hippocampus and cerebellum of triple knockout mice also exhibit reeler-like malformations, although less penetrant than the cortical defects. Dab1 phosphorylation is impaired in mice lacking ephrinB3 and this effect is strongly enhanced in neurons lacking all ephrin ligands. Moreover, activation of ephrinB3 reverse signaling induces Dab1phosphorylation in reeler primary neurons. In agreement with an important regulatory function of ephrinBs in Reelin signaling, activation of ephrinB3 reverse signaling is even able to rescue reeler defects in cortical layering in organotypic slice cultures. In summary, all these results identify ephrinBs as co-receptors for Reelin signaling, playing essential roles in neuronal migration during the development of cortex, hippocampus and cerebellum (Sentürk et al., 2011).
Angiogenesis, the formation of new blood vessels from existing ones, is a fundamental biological process required for embryonic development; it also plays an important role during postnatal organ development and various physiological and pathological remodeling processes in the adult organism. Vascular endothelial growth factor (VEGF) and its main receptor, VEGF receptor-2 (VEGFR-2), play a central role in angiogenesis. VEGFR-2 expression is strongly upregulated in angiogenic vessels, but the mechanisms regulating VEGFR-2 expression are not well understood. We found in this study that the G-protein α subunit Gα13 plays an important role in the regulation of VEGFR-2 expression. In vitro, we found that knockdown of Gα13 reduced VEGFR-2 expression in human umbilical vein endothelial cells and impaired responsiveness to VEGF-A. This phenotype was rescued by adenoviral normalization of VEGFR-2 expression. Gα13-dependent VEGFR-2 expression involved activation of the small GTPase RhoA and transcription factor NF-κB; it was abrogated by deletion of the NF-κB binding site at position -84 of the VEGFR-2 promoter. In vivo, endothelial cell-specific loss of Gα13 resulted in reduced VEGFR-2 expression, impaired responsiveness towards VEGF-A in Matrigel assays, and reduced retinal angiogenesis. Importantly, also tumor vascularization was diminished in the absence of endothelial Gα13, resulting in reduced tumor growth. Taken together, we identified Gα13-dependent NF-κB activation as a new pathway underlying the transcriptional regulation of VEGFR-2 during retinal and tumor angiogenesis.